Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Published:2016-01-21 Issue:3 Volume:127 Page:303-309
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Thompson Philip A.¹,Tam Constantine S.²,O’Brien Susan M.¹,Wierda William G.¹,Stingo Francesco³,Plunkett William⁴,Smith Susan C.¹,Kantarjian Hagop M.¹,Freireich Emil J.¹,Keating Michael J.¹

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia;

3. Department of Biostatistics, and

4. Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points FCR-treated chronic lymphocytic leukemia patients with mutated IGHV gene achieve long-term PFS, with a plateau on the PFS curve. MRD-negativity posttreatment is highly predictive of long-term PFS, particularly in patients with mutated IGHV gene.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/3/303/1393462/303.pdf

Reference26 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.;Hallek;Lancet,2010

2. TP53 mutation and survival in chronic lymphocytic leukemia.;Zenz;J Clin Oncol,2010

3. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.;Rossi;Blood,2014

4. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.;Tam;Blood,2008

5. Allotransplantation for chronic lymphocytic leukemia.;Dreger;Hematology Am Soc Hematol Educ Program,2009

Cited by 438 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib reversal of immune exhaustion in CLL;Blood;2024-01-04

2. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

3. Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023;memo - Magazine of European Medical Oncology;2023-12-05

4. Predictive and prognostic molecular biomarkers in lymphomas;Pathology;2023-12

5. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up;BLOOD;2023